Tags

Type your tag names separated by a space and hit enter

Burkholderia vaccines: are we moving forward?

Abstract

The genus Burkholderia consists of diverse species which includes both "friends" and "foes." Some of the "friendly" Burkholderia spp. are extensively used in the biotechnological and agricultural industry for bioremediation and biocontrol. However, several members of the genus including B. pseudomallei, B. mallei, and B. cepacia, are known to cause fatal disease in both humans and animals. B. pseudomallei and B. mallei are the causative agents of melioidosis and glanders, respectively, while B. cepacia infection is lethal to cystic fibrosis (CF) patients. Due to the high rate of infectivity and intrinsic resistance to many commonly used antibiotics, together with high mortality rate, B. mallei and B. pseudomallei are considered to be potential biological warfare agents. Treatments of the infections caused by these bacteria are often unsuccessful with frequent relapse of the infection. Thus, we are at a crucial stage of the need for Burkholderia vaccines. Although the search for a prophylactic therapy candidate continues, to date development of vaccines has not advanced beyond research to human clinical trials. In this article, we review the current research on development of safe vaccines with high efficacy against B. pseudomallei, B. mallei, and B. cepacia. It can be concluded that further research will enable elucidation of the potential benefits and risks of Burkholderia vaccines.

Authors+Show Affiliations

Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23386999

Citation

Choh, Leang-Chung, et al. "Burkholderia Vaccines: Are We Moving Forward?" Frontiers in Cellular and Infection Microbiology, vol. 3, 2013, p. 5.
Choh LC, Ong GH, Vellasamy KM, et al. Burkholderia vaccines: are we moving forward? Front Cell Infect Microbiol. 2013;3:5.
Choh, L. C., Ong, G. H., Vellasamy, K. M., Kalaiselvam, K., Kang, W. T., Al-Maleki, A. R., Mariappan, V., & Vadivelu, J. (2013). Burkholderia vaccines: are we moving forward? Frontiers in Cellular and Infection Microbiology, 3, 5. https://doi.org/10.3389/fcimb.2013.00005
Choh LC, et al. Burkholderia Vaccines: Are We Moving Forward. Front Cell Infect Microbiol. 2013;3:5. PubMed PMID: 23386999.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Burkholderia vaccines: are we moving forward? AU - Choh,Leang-Chung, AU - Ong,Guang-Han, AU - Vellasamy,Kumutha M, AU - Kalaiselvam,Kaveena, AU - Kang,Wen-Tyng, AU - Al-Maleki,Anis R, AU - Mariappan,Vanitha, AU - Vadivelu,Jamuna, Y1 - 2013/02/05/ PY - 2012/08/10/received PY - 2013/01/20/accepted PY - 2013/2/7/entrez PY - 2013/2/7/pubmed PY - 2013/2/7/medline KW - Burkholderia cepacia KW - Burkholderia mallei KW - Burkholderia pseudomallei KW - cystic fibrosis KW - glanders KW - melioidosis KW - vaccine SP - 5 EP - 5 JF - Frontiers in cellular and infection microbiology JO - Front Cell Infect Microbiol VL - 3 N2 - The genus Burkholderia consists of diverse species which includes both "friends" and "foes." Some of the "friendly" Burkholderia spp. are extensively used in the biotechnological and agricultural industry for bioremediation and biocontrol. However, several members of the genus including B. pseudomallei, B. mallei, and B. cepacia, are known to cause fatal disease in both humans and animals. B. pseudomallei and B. mallei are the causative agents of melioidosis and glanders, respectively, while B. cepacia infection is lethal to cystic fibrosis (CF) patients. Due to the high rate of infectivity and intrinsic resistance to many commonly used antibiotics, together with high mortality rate, B. mallei and B. pseudomallei are considered to be potential biological warfare agents. Treatments of the infections caused by these bacteria are often unsuccessful with frequent relapse of the infection. Thus, we are at a crucial stage of the need for Burkholderia vaccines. Although the search for a prophylactic therapy candidate continues, to date development of vaccines has not advanced beyond research to human clinical trials. In this article, we review the current research on development of safe vaccines with high efficacy against B. pseudomallei, B. mallei, and B. cepacia. It can be concluded that further research will enable elucidation of the potential benefits and risks of Burkholderia vaccines. SN - 2235-2988 UR - https://www.unboundmedicine.com/medline/citation/23386999/Burkholderia_vaccines:_are_we_moving_forward L2 - https://doi.org/10.3389/fcimb.2013.00005 DB - PRIME DP - Unbound Medicine ER -